

ICM ICM 2025 Question B12: “What are the minimum data set for studying orthopaedic infections?”

Austin E. Wininger, Saad Tarabichi, Konstantinos Malizos, Minjae Lee, Nicolas S. Piuze, Alison Klika, Stephen L. Kates, Antonia F. Chen, Joshua S. Bingham

RESPONSE/RECOMMENDATION: There appears to be marked variation in the reporting of data regarding orthopaedic infections, and as a result there is limited comparability across the orthopaedic literature. Future studies should strive to include a minimum of 300 patients per comparison group with 1-year minimum follow-up and key data on patient characteristics (e.g., systemic and extremity compromising factors), operative factors (e.g., indication, need for transfusion, type of implants used), diagnostic criteria (e.g., serum and synovial fluid studies, operative cultures), and postoperative outcomes (e.g., patient-reported outcome measures).

LEVEL OF EVIDENCE: Expert Opinion

DELEGATE VOTE: Agree: [% vote], Disagree: [%], Abstain: [%]

RATIONALE: Infection remains a major cause of morbidity and mortality in patients undergoing orthopaedic procedures [1]. In recent years, we have witnessed a surge in the use of large data sets such as administrative datasets to study orthopaedic infections. While these datasets hold large numbers of patients, they often lack the granularity necessary to study how different infection management protocols impact treatment outcomes in orthopaedics [2-6]. Additionally, there is still marked variability in the reporting of registry data, resulting in major challenges when both aggregating data or comparing results across different studies [7]. In order to appropriately investigate orthopaedic infections, a clearer definition of the minimum data set is paramount to ensuring the collection of accurate clinical data that is translatable to meaningful improvements in patient care [8,9]. This can be stratified into preoperative, intraoperative, and postoperative variables. Given that infection rates range from roughly 1-5% following orthopaedic surgeries with implants, it may be reasonable to propose that a minimum patient sample size of 300 patients per comparison group is needed to reduce the likelihood of underpowered analyses and type II errors [10].

Host optimization is an important factor preoperatively with regard to the prevention and treatment of orthopaedic infections [11-14]. The McPherson classification has long been used in patients with hip and knee periprosthetic joint infection (PJI), which highlights the importance of infection type (early postoperative, hematogenous, or late chronic), systemic host compromising factors, and local extremity compromising factors [15,16]. Patient characteristics such as obesity, diabetes, inflammatory arthritis, immunosuppressive medications, anemia, renal disease, malnutrition, mental health disorders, nicotine use, alcohol abuse, and human immunodeficiency virus (HIV) infection status are also well recognized modifiable risk factors in this patient population [17-19]. Preoperative laboratory values such as hemoglobin A1c, 25-hydroxyvitamin D, albumin, prealbumin, total protein, total lymphocyte count, iron, and transferrin have also been shown to be predictors for infection in patients undergoing orthopaedic procedures [20-23]. It is also important to identify whether a patient has had prior surgery, has a history of infection at the same surgical site, or is being administered chronic antibiotic suppression. At a minimum, patient age, sex, body mass index, relevant surgical history, and compromising medical comorbidities must be reported. Including socioeconomic factors individually or through a comprehensive approach such as the Area Deprivation Index (ADI) in the United States, large datasets studying infection can reveal critical disparities in healthcare utilization and recovery. Addressing these factors is essential to beginning to understand and mitigate the influence of socioeconomic disadvantage on orthopaedic surgery postoperative complications and infection [24-30].

Operative characteristics have also been shown to be a factor in the development of orthopaedic infections [13,31-33]. Some technical aspects of surgery, such as soft tissue handling, wound management, operating room traffic, and cleaning of instruments, are difficult to standardize and report. However, other variables, such as surgical indication, operative time, estimated blood loss, need for transfusion, general type of implants used (e.g., primary versus revision components), and length of stay, are routinely recorded in the electronic medical record and should be included in the minimum data set for orthopaedic infections.

Serum and synovial fluid laboratory studies, in combination with operative findings and cultures, are used to diagnose orthopaedic infections [34]. Microbiology data and pathogen identification, when available, are valuable and may impact the medical and surgical treatment plan [35,36]. Studies should be transparent and report the actual data from which the diagnosis of an orthopaedic infection is made (e.g., utilizing the 2018 International Consensus Meeting or the 2021 European Bone and Joint Infection Society criteria for hip and knee PJI) [37,38].

Lastly, there is a paucity of literature on the postoperative criteria used to define treatment success for orthopaedic infections [39]. The outcomes for the management of orthopaedic infection include infection control with no continued antibiotic therapy, infection control with suppressive antibiotic therapy, retained spacer, need for reoperation, and death. The need for reoperation could be for aseptic or septic reasons, and the time to reoperation or death is important to note, as reoperation or death less than 1 year after the treatment of an orthopaedic infection is more likely to represent a treatment failure [40,41]. The minimum follow-up to report treatment outcomes for orthopaedic infections is unknown, but recent literature has suggested a minimum one-year follow-up after treatment for hip and knee periprosthetic joint infection and fracture-related infection and up to 5-years to determine PJI 'remission' [42-44]. With the current emphasis on patient-centered and value-based healthcare, patient-reported outcome measures (PROMs) have become an important component [45,46]. There are general health and condition-specific PROMs, which can be combined to paint a more complete picture of the overall outcome, as infection eradication does not always equate to patient satisfaction. Thus, patients should be followed for a minimum of one year following treatment of an orthopaedic infection with PROMs being tracked preoperatively and postoperatively. A standardized approach to reporting PROMs is critical in this context to ensure that the data collected reflects true clinical relevance. Orr et al. emphasize that a value-driven healthcare model requires accurate analysis and reporting of PROMs to identify patients who don't meet clinical thresholds. Using the "clinical relevance ratio," which assesses outcomes based on MCID and PASS, provides an unbiased measure of treatment effectiveness by focusing on the proportion of patients achieving meaningful improvements, thus enhancing the utility of PROMs in assessing satisfaction and success in orthopaedic care [47].

Conclusion:

In summary, with the current knowledge and available evidence regarding orthopaedic infections, it is reasonable to propose that the aforementioned variables comprise the minimum data set for studies related to orthopaedic infection (**Table 1**). Moving forward, new literature should strive to report this data to maximize generalizability and comparability across the orthopaedic literature.

Table 1. Criteria for the minimum data set to study orthopaedic infections.

Sample Size	300 patients per comparison group
Patient Factors	Age
	Sex
	Body mass index
	Relevant surgical history
	Host compromising factors (e.g., diabetes, autoimmune disease, immunosuppressive medication, renal disease, or malnutrition)
	Extremity compromising factors (e.g., soft tissue loss or vascular insufficiency)
	Socioeconomic factors (e.g., area deprivation index)
Surgical Factors	Surgical indication (e.g., elective vs traumatic)
	Operative time
	Estimated blood loss
	Need for transfusion
	Type of implants used (e.g., primary vs revision components)
	Length of stay
Diagnostic Criteria	Serum laboratory studies (ESR, CRP)
	Synovial fluid analysis (if applicable)
	Operative culture data
Outcomes	Minimum 1-year follow-up
	General health and condition-specific PROMs

CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, PROMs = patient reported outcome measures

References

1. Lee C, Mayer E, Bernthal N, Wenke J, O'Toole RV. Orthopaedic infections: what have we learned? *OTA Int.* 2023 May 4;6(2 Suppl):e250. doi: 10.1097/OI9.0000000000000250.
2. Lethbridge LN, Richardson CG, Dunbar MJ. Measuring Surgical Site Infection From Linked Administrative Data Following Hip and Knee Replacement. *J Arthroplasty.* 2020 Feb;35(2):528-533. doi: 10.1016/j.arth.2019.09.025.
3. Jin X, Gallego Luxan B, Hanly M, Pratt NL, Harris I, de Steiger R, Graves SE, Jorm L. Estimating incidence rates of periprosthetic joint infection after hip and knee arthroplasty for osteoarthritis using linked registry and administrative health data. *Bone Joint J.* 2022 Sep;104-B(9):1060-1066. doi: 10.1302/0301-620X.104B9.BJJ-2022-0116.R1.
4. Kamp MC, Liu WY, Goosen JHM, Rijnen WHC, van Steenberghe LN, van der Weegen W; Regional Prosthetic Joint Infection Working Group. Mismatch in Capture of Periprosthetic Joint Infections Between the Dutch Arthroplasty Register (LROI) and a Detailed Regional Periprosthetic Joint Infection Registry. *J Arthroplasty.* 2022 Jan;37(1):126-131. doi: 10.1016/j.arth.2021.09.001.
5. Springer BD, Cahue S, Etkin CD, Lewallen DG, McGrory BJ. Infection burden in total hip and knee arthroplasties: an international registry-based perspective. *Arthroplast Today.* 2017 Jun 20;3(2):137-140. doi: 10.1016/j.artd.2017.05.003.

6. Taherpour N, Mehrabi Y, Seifi A, Eshrati B, Hashemi Nazari SS. Epidemiologic characteristics of orthopedic surgical site infections and under-reporting estimation of registries using capture-recapture analysis. *BMC Infect Dis.* 2021 Jan 4;21(1):3. doi: 10.1186/s12879-020-05687-z.
7. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *Lancet.* 2009 Jul 4;374(9683):86-9. doi: 10.1016/S0140-6736(09)60329-9.
8. Gargon E, Gurung B, Medley N, Altman DG, Blazeby JM, Clarke M, Williamson PR. Choosing important health outcomes for comparative effectiveness research: a systematic review. *PLoS One.* 2014 Jun 16;9(6):e99111. doi: 10.1371/journal.pone.0099111.
9. Svensson-Ranallo PA, Adam TJ, Sainfort F. A framework and standardized methodology for developing minimum clinical datasets. *AMIA Jt Summits Transl Sci Proc.* 2011;2011:54-8.
10. Kim J, Seo BS. How to calculate sample size and why. *Clin Orthop Surg.* 2013 Sep;5(3):235-42. doi: 10.4055/cios.2013.5.3.235.
11. Asadi K, Tehrany PM, Salari A, Ghorbani Vajargah P, Mollaei A, Sarafi M, Ashoobi MT, Esmaeili Delshad MS, Takasi P, Fouladpour A, Karkhah S, Farzan R, Aris A. Prevalence of surgical wound infection and related factors in patients after long bone surgery: A systematic review and meta-analysis. *Int Wound J.* 2023 Dec;20(10):4349-4363. doi: 10.1111/iwj.14300.
12. Chen AF, Brown GA. Management of Surgical Site Infections. *J Am Acad Orthop Surg.* 2020 Mar 15;28(6):e238-e241. doi: 10.5435/JAAOS-D-19-00552.
13. Tarabichi S, Parvizi J. Prevention of surgical site infection: a ten-step approach. *Arthroplasty.* 2023 Apr 8;5(1):21. doi: 10.1186/s42836-023-00174-7.
14. Zaboli Mahdiabadi M, Farhadi B, Shahroudi P, Mohammadi M, Omrani A, Mohammadi M, Hekmati Pour N, Hojjati H, Najafi M, Majd Teimoori Z, Farzan R, Salehi R. Prevalence of surgical site infection and risk factors in patients after knee surgery: A systematic review and meta-analysis. *Int Wound J.* 2024 Feb;21(2):e14765. doi: 10.1111/iwj.14765.
15. Amanatullah D, Dennis D, Oltra EG, Marcelino Gomes LS, Goodman SB, Hamlin B, Hansen E, Hashemi-Nejad A, Holst DC, Komnos G, Koutalos A, Malizos K, Martinez Pastor JC, McPherson E, Meermans G, Mooney JA, Mortazavi J, Parsa A, Pécora JR, Pereira GA, Martos MS, Shohat N, Shope AJ, Zullo SS. Hip and Knee Section, Diagnosis, Definitions: Proceedings of International Consensus on Orthopedic Infections. *J Arthroplasty.* 2019 Feb;34(2S):S329-S337. doi: 10.1016/j.arth.2018.09.044.
16. McPherson EJ, Woodson C, Holtom P, Roidis N, Shufelt C, Patzakis M. Periprosthetic total hip infection: outcomes using a staging system. *Clin Orthop Relat Res.* 2002 Oct;(403):8-15.
17. McLaren AC, Lundy DW. AAOS Systematic Literature Review: Summary on the Management of Surgical Site Infections. *J Am Acad Orthop Surg.* 2019 Aug 15;27(16):e717-e720. doi: 10.5435/JAAOS-D-18-00653.
18. Perry KI, Hanssen AD. Orthopaedic Infection: Prevention and Diagnosis. *J Am Acad Orthop Surg.* 2017 Feb;25 Suppl 1:S4-S6. doi: 10.5435/JAAOS-D-16-00634.
19. Tubb CC, Polkowski GG, Krause B. Diagnosis and Prevention of Periprosthetic Joint Infections. *J Am Acad Orthop Surg.* 2020 Apr 15;28(8):e340-e348. doi: 10.5435/JAAOS-D-19-00405.
20. Antonelli B, Chen AF. Reducing the risk of infection after total joint arthroplasty: preoperative optimization. *Arthroplasty.* 2019 Aug 1;1(1):4. doi: 10.1186/s42836-019-0003-7.
21. Birinci M, Hakyemez ÖS, Geçkalan MA, Mutlu M, Yildiz F, Bilgen ÖF, Azboy İ. Effect of Vitamin D Deficiency on Periprosthetic Joint Infection and Complications After Primary Total Joint Arthroplasty. *J Arthroplasty.* 2024 Sep;39(9S2):S151-S157. doi: 10.1016/j.arth.2024.05.012.
22. Shohat N, Goswami K, Tarabichi M, Sterbis E, Tan TL, Parvizi J. All Patients Should Be Screened for Diabetes Before Total Joint Arthroplasty. *J Arthroplasty.* 2018 Jul;33(7):2057-2061. doi: 10.1016/j.arth.2018.02.047.
23. Tarabichi M, Shohat N, Kheir MM, Adelani M, Brigati D, Kearns SM, Patel P, Clohisy JC, Higuera CA, Levine BR, Schwarzkopf R, Parvizi J, Jiranek WA. Determining the Threshold for

- HbA1c as a Predictor for Adverse Outcomes After Total Joint Arthroplasty: A Multicenter, Retrospective Study. *J Arthroplasty*. 2017 Sep;32(9S):S263-S267.e1.
24. Benyamini B, Hadad MJ, Pasqualini I, Khan ST, Jin Y; Cleveland Clinic Adult Reconstruction Research; Piuze NS. Neighborhood Socioeconomic Disadvantage May Influence 1-Year Patient-Reported Outcome Measures After Total Hip Arthroplasty. *J Arthroplasty*. 2024 Oct 16:S0883-5403(24)01020-9. doi: 10.1016/j.arth.2024.10.007.
 25. Gordon AM, Ng MK, Elali F, Piuze NS, Mont MA. A Nationwide Analysis of the Impact of Socioeconomic Status on Complications and Health Care Utilizations After Total Knee Arthroplasty Using the Area Deprivation Index: Consideration of the Disadvantaged Patient. *J Arthroplasty*. 2024 Sep;39(9):2166-2172. doi: 10.1016/j.arth.2024.04.028.
 26. Hadad MJ, Pasqualini I, Klika AK, Jin Y, Deren ME, Krebs VE, Murray TG, Piuze NS. High Area Deprivation Index is Associated With Not Achieving the Patient-acceptable Symptom State After TKA. *Clin Orthop Relat Res*. 2024 Aug 1;482(8):1428-1438. doi: 10.1097/CORR.0000000000003040.
 27. Hadad MJ, Rullán-Oliver P, Grits D, Zhang C, Emara AK, Molloy RM, Klika AK, Piuze NS. Racial Disparities in Outcomes After THA and TKA Are Substantially Mediated by Socioeconomic Disadvantage Both in Black and White Patients. *Clin Orthop Relat Res*. 2023 Feb 1;481(2):254-264. doi: 10.1097/CORR.0000000000002392.
 28. Jevnikar BE, Huffman N, Pasqualini I, Zhang C, Klika AK, Deren ME; CCARR Corporate Authorship; Piuze NS. Neighborhood Socioeconomic Disadvantage is Associated With Increased Health Care Utilization After Septic and Aseptic Revision Total Hip Arthroplasty. *J Arthroplasty*. 2024 Sep 16:S0883-5403(24)00951-3. doi: 10.1016/j.arth.2024.09.014.
 29. Jevnikar BE, Huffman N, Roth A, Klika AK, Deren ME, Zhang C, Piuze NS; CCARR Corporate Authorship. Impacts of neighborhood deprivation on septic and aseptic revision total knee arthroplasty outcomes: A comprehensive analysis using the area deprivation index. *Knee*. 2024 Sep 5;51:74-83. doi: 10.1016/j.knee.2024.08.006.
 30. Pasqualini I, Tidd JL, Klika AK, Jones G, Johnson JK, Piuze NS. High Risk of Readmission After THA Regardless of Functional Status in Patients Discharged to Skilled Nursing Facility. *Clin Orthop Relat Res*. 2024 Jul 1;482(7):1185-1192. doi: 10.1097/CORR.0000000000002950.
 31. Bohl DD, Ondeck NT, Darrih B, Hannon CP, Fillingham YA, Della Valle CJ. Impact of Operative Time on Adverse Events Following Primary Total Joint Arthroplasty. *J Arthroplasty*. 2018 Jul;33(7):2256-2262.e4. doi: 10.1016/j.arth.2018.02.037.
 32. Tantillo T, Petrone B, Stapleton E, Frane N, Matai P, Lutsky L, Schilling M, Armellino D, Katsigiorgis G, Bitterman A. The Effect of Operating Room Size on Orthopaedic Surgical Site Infection Rates. *J Am Acad Orthop Surg*. 2021 Dec 1;29(23):1009-1016. doi: 10.5435/JAAOS-D-20-01022.
 33. Tarabichi S, Chisari E, Van Nest DS, Krueger CA, Parvizi J. Surgical Helmets Used During Total Joint Arthroplasty Harbor Common Pathogens: A Cautionary Note. *J Arthroplasty*. 2022 Aug;37(8):1636-1639. doi: 10.1016/j.arth.2022.03.066.
 34. Higgins E, Suh GA, Tande AJ. Enhancing Diagnostics in Orthopedic Infections. *J Clin Microbiol*. 2022 Jun 15;60(6):e0219621. doi: 10.1128/jcm.02196-21.
 35. Villa JM, Pannu TS, Theeb I, Buttaro MA, Oñativia JI, Carbo L, Rienzi DH, Fregeiro JI, Kornilov NN, Bozhkova SA, Sandiford NA, Piuze NS, Higuera CA, Kendoff DO. International Organism Profile of Periprosthetic Total Hip and Knee Infections. *J Arthroplasty*. 2021 Jan;36(1):274-278. doi: 10.1016/j.arth.2020.07.020.
 36. Wang B, Wang Q, Hamushan M, Yu J, Jiang F, Li M, Guo G, Tang J, Han P, Shen H. Trends in microbiological epidemiology of orthopedic infections: a large retrospective study from 2008 to 2021. *BMC Infect Dis*. 2023 Aug 31;23(1):567. doi: 10.1186/s12879-023-08471-x.

37. McNally M, Sousa R, Wouthuyzen-Bakker M, Chen AF, Soriano A, Vogely HC, Clauss M, Higuera CA, Trebše R. The EBJIS definition of periprosthetic joint infection. *Bone Joint J.* 2021 Jan;103-B(1):18-25. doi: 10.1302/0301-620X.103B1.BJJ-2020-1381.R1.
38. Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF, Shohat N. The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria. *J Arthroplasty.* 2018 May;33(5):1309-1314.e2. doi: 10.1016/j.arth.2018.02.078.
39. Tan TL, Goswami K, Fillingham YA, Shohat N, Rondon AJ, Parvizi J. Defining Treatment Success After 2-Stage Exchange Arthroplasty for Periprosthetic Joint Infection. *J Arthroplasty.* 2018 Nov;33(11):3541-3546. doi: 10.1016/j.arth.2018.06.015.
40. Slullitel PA, Oñativia JI, Cima I, Zanotti G, Comba F, Piccaluga F, Buttarro MA. Patients with no recurrence of infection five years after two-stage revision hip arthroplasty may be classified as periprosthetic infection 'in remission'. *Bone Joint J.* 2021 Jan;103-B(1):79-86. doi: 10.1302/0301-620X.103B1.BJJ-2020-0955.R1.
41. Diaz-Ledezma C, Higuera CA, Parvizi J. Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus. *Clin Orthop Relat Res.* 2013 Jul;471(7):2374-82. doi: 10.1007/s11999-013-2866-1.
42. Fillingham YA, Della Valle CJ, Suleiman LI, Springer BD, Gehrke T, Bini SA, Segreti J, Chen AF, Goswami K, Tan TL, Shohat N, Diaz-Ledezma C, Schwartz AJ, Parvizi J. Definition of Successful Infection Management and Guidelines for Reporting of Outcomes After Surgical Treatment of Periprosthetic Joint Infection: From the Workgroup of the Musculoskeletal Infection Society (MSIS). *J Bone Joint Surg Am.* 2019 Jul 17;101(14):e69. doi: 10.2106/JBJS.19.00062.
43. Xu C, Tan TL, Li WT, Goswami K, Parvizi J. Reporting Outcomes of Treatment for Periprosthetic Joint Infection of the Knee and Hip Together With a Minimum 1-Year Follow-Up is Reliable. *J Arthroplasty.* 2020 Jul;35(7):1906-1911.e5. doi: 10.1016/j.arth.2020.02.017.
44. Zalavras CG, Aerden L, Declercq P, Belmans A, Metsemakers WJ. Ninety-Day Follow-up Is Inadequate for Diagnosis of Fracture-related Infections in Patients with Open Fractures. *Clin Orthop Relat Res.* 2022 Jan 1;480(1):139-146. doi: 10.1097/CORR.0000000000001911.
45. Franklin PD, Bond CP, Rothrock NE, Cella D. Strategies for Effective Implementation of Patient-Reported Outcome Measures in Arthroplasty Practice. *J Bone Joint Surg Am.* 2021 Dec 15;103(24):e97. doi: 10.2106/JBJS.20.02072.
46. Ingelsrud LH, Wilkinson JM, Overgaard S, Rolfson O, Hallstrom B, Navarro RA, Turner M, Karmakar-Hore S, Webster G, Slawomirski L, Sayers A, Kendir C, de Bienassis K, Klazinga N, Dahl AW, Bohm E. How do Patient-reported Outcome Scores in International Hip and Knee Arthroplasty Registries Compare? *Clin Orthop Relat Res.* 2022 Oct 1;480(10):1884-1896. doi: 10.1097/CORR.0000000000002306.
47. Orr MN, Klika AK, Gagnier JJ, Bhandari M, Piuze NS. A Call for a Standardized Approach to Reporting Patient-Reported Outcome Measures: Clinical Relevance Ratio. *J Bone Joint Surg Am.* 2021 Nov 17;103(22):e91. doi: 10.2106/JBJS.21.00030.